Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare

Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis

(2020) Silke Frey et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

(2019) Hervé Bachelez et al.   NEW ENGLAND JOURNAL OF MEDICINE

388 Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways

(2019) P. Baum et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pustular psoriasis and related pustular skin diseases

(2018) H. Bachelez   BRITISH JOURNAL OF DERMATOLOGY

Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review

(2018) Alexander Boehner et al.   EXPERIMENTAL DERMATOLOGY

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study

(2018) Shigetoshi Sano et al.   JOURNAL OF DERMATOLOGY

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations

(2018) Dagmar Wilsmann-Theis et al.   JOURNAL OF DERMATOLOGY

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

(2018) Hideki Fujita et al.   JOURNAL OF DERMATOLOGY

IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis

(2017) Andrew Johnston et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

European consensus statement on phenotypes of pustular psoriasis

(2017) A.A. Navarini et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

(2016) K. Yamasaki et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

(2016) Hidehisa Saeki et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study

(2016) Shinichi Imafuku et al.   JOURNAL OF DERMATOLOGY

IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis

(2016) Gabriella Giancane et al.   Frontiers in Pharmacology

Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients

(2015) Ting-Shun Wang et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris

(2015) Dorottya M. Berki et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking

(2014) Niovi Setta-Kaffetzi et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

(2014) H. Saeki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia

(2013) Siew Eng Choon et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases

(2013) Silvia Federici et al.   Frontiers in Immunology

Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation

(2012) Amanda Robinson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

(2011) Slaheddine Marrakchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE